Appropriate knowledge of the metabolic properties of cancer cells compared with normal ones is a major prerequisite in order to elucidate the mechanisms responsible for abnormal cell proliferation and dysregulated biomass production. A relevant paradigm is the not-yet-fully-perfected basis of the Warburg effect and of the underlying pathways of glucose and glutamine utilization in tumor cells (1). On the other hand, peculiarities in cancer cell metabolism are the result of both germline and somatic mutations, but little is known in general on how these mutations translate into cancer-specific phenotypes, mostly to selected enzyme deficiencies or to imbalances in the regulation and the coordination of metabolic fluxes in tumor cells. This limitation reflects a still-insufficient integration of emerging data from high-throughput technologies and of the various steps of experimental analysis that characterize the "omics" field.
Appropriate knowledge of the metabolic properties of cancer cells compared with normal ones is a major prerequisite in order to elucidate the mechanisms responsible for abnormal cell proliferation and dysregulated biomass production. A relevant paradigm is the not-yet-fully-perfected basis of the Warburg effect and of the underlying pathways of glucose and glutamine utilization in tumor cells (1) . On the other hand, peculiarities in cancer cell metabolism are the result of both germline and somatic mutations, but little is known in general on how these mutations translate into cancer-specific phenotypes, mostly to selected enzyme deficiencies or to imbalances in the regulation and the coordination of metabolic fluxes in tumor cells. This limitation reflects a still-insufficient integration of emerging data from high-throughput technologies and of the various steps of experimental analysis that characterize the "omics" field.
While a general advancement in the area is legitimately expected from the development of computational tools (1), it is well documented that wet science, eg, genome-wide association studies and metabolic approaches, is strictly required. To this purpose, it is interesting to note that, for example, cancer-causing mutations associated with enzyme deficiencies are generally investigated according to the following multistep strategy:
1. Identify a primary metabolic abnormality associated with malignancy, select a suitable model system, and characterize the defective enzymatic step. 2. Elucidate the molecular mechanisms of deficiency, from gene(s) to enzyme protein(s) or interacting partners. If possible, reconstruct the cancer-causing mutation in vitro and validate the consequent molecular abnormality. 3. Identify enzyme deficiency-related alterations via metabolomics, definition of metabolic precursors (eg, glucose, glutamine, others), and mapping of global metabolic network in the tumor cell. 4. Return to step 2 with the aim of correcting site-specific molecular alterations causing tumorigenesis. 5. Validate the models obtained through step 4 by means of suitable approaches of metabolic engineering.
In this issue of the Journal, Saxena et al. (2) addressed the role of mutations in the SDHB subunit of succinate dehydrogenase (SDH) known to cause familial cancer syndromes. Starting from classical biochemistry and using an SDHB-deficient renal cell carcinoma line (UOK269), they went through steps 1 to 3 of the above scheme and set a reasonable basis for further investigations aimed at developing therapeutic approaches for SDHrelated and possibly other Krebs cycle-related cancers.
SDH, a long-known tumor suppressor (3), is a mitochondrial enzyme catalyzing the conversion of succinate to fumarate in the Krebs cycle and functioning as complex II in the respiratory chain involved in oxidative phosphorylation, ie, ATP synthesis in mitochondria. The structure of SDH is made up of four subunits, SDHA, SDHB, SDHC, and SDHD (4). A previous study by the same group demonstrated a critical role of two highly conserved leucine (or isoleucine)/tyrosine/arginine (L(I)YR) tripeptide motifs present in the SDHB subunit in driving the correct assembly (and a normal function) of SDH to yield the final structure of the whole complex II (5). Specifically, they identified the above role in the transfer of nascent iron-sulfur (Fe-S) clusters from a primary scaffold (defined ISCU) to SDHB. The transfer requires the formation of a dedicated complex between ISCU, SDHB, the HSPA9 chaperone, and the HSC20 cochaperone, which was investigated with elegant and sound experiments (5). This molecular machinery functions to mediate incorporation of the Fe-S clusters within the complete structure of complex II (6 (2) encompass elucidation of disease-causing mechanisms to include the identification of metabolic peculiarities that are potential targets for selective therapies. Remarkably, they analyzed and classified several SDHB missense mutations and reported that those that affect the two L(I)YR motifs or the eleven Fe-cluster cysteinyl ligands account for 37% of the known SDHB-related tumors.
Beyond the deep insight this study provides in the field, it also opens different questions. One of these starts from the high level of methylation of DNA CpG islands in UOK269 cells, similar to the hypermethylation phenotype reported by Letouzé et al. (8) in paragangliomas harboring SDH mutations. Another possibly related question concerns the finding of high levels of HIF1-α protein in the same cell line (2) . The authors tentatively relate both observations to the recent proposal that succinate, similar to fumarate and (R)-2-hydroxyglutarate, acts as an "oncometabolite" (9) (10) (11) (12) . This means that increased succinate in UOK269 cells might inhibit the ten-eleven translocation (TET) family of α-ketoglutarate-dependent dioxygenases responsible for demethylation of 5'-methylcytosine in DNA, the consequent increase of the levels of methylated DNA (as observed in this study), and the HIF1-α prolyl hydroxylase. The latter succinateinduced effect would lead to HIF1-α protein stabilization under normoxic conditions, with activation of genes that promote angiogenesis and anaerobic glycolysis (13) . It is significant that both facts seem to identify succinate as an "epigenetic hacker" (14) , providing a link between Krebs cycle dysfunctions and epigenomic alterations in cancer. Obviously, these data and their implications bear relevance to possible epigenetic therapeutic and preventive interventions.
Finally, it would be desirable to extend this study to evaluate the possibility of redox control of glutamine utilization in SDHB-related tumors. This possibility, which would open the way for targeted antitumor drug discovery, is centered on the NAD + /NADH, on the NADP + /NADPH ratios, and on the redox metabolic processes that regulate them to cause reductive carboxylation of glutamine-derived α-ketoglutarate to yield isocitrate and citrate (1) . Such diversion from a normal to a cancer-specific metabolism seems to involve nicotinamide nucleotide transhydrogenase (NTT), a mitochondrial enzyme that reduces NADP + at the expense of NADH (1). Accordingly, proper engineering of NAD(H) metabolism in cancer cells seems to represent a promising approach to therapies and prevention strategies.
